ArticleEMBO reports2020
One repressor to rule them all: ANCO1 links YAP and AIB1.
Article in EMBO reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 3 citations in OpenAlex.
- Yorkie/YAP Interactors: Fine-Tuning the Hippo Pathway Output.Cold Spring Harbor perspectives in biology · 2026Article
- Transcriptional co-activators: emerging roles in signaling pathways and potential therapeutic targets for diseases.Signal transduction and targeted therapy · 2023Review
- SRC-3, a Steroid Receptor Coactivator: Implication in Cancer.International journal of molecular sciences · 2021Review
- One repressor to rule them all: ANCO1 links YAP and AIB1.EMBO reports · 2020Article
Corrections and comments
- Comment on
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The transcriptional co-activators YAP and AIB1 individually promote breast cancer progression, but are not known to be mechanistically linked. A study published in this issue of EMBO Reports [1] now shows that YAP-AIB1 form a physical complex in breast epithelial cells that cooperates in both activation and, unexpectedly, repression of key breast cancer genes. The repressive effect is due to the recruitment of ANCO1, a previously defined AIB1 interactor [2] that binds and inhibits the YAP-AIB1 complex. These data identify ANCO1 as a candidate tumor suppressor through YAP-AIB1 inhibition and could hint at a broader crosstalk between pathways that utilize YAP and AIB1 to control epithelial homeostasis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.